MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202528069297 A) filed by Zydus Lifesciences Limited, Ahmedabad, Gujarat, on July 21, for 'pharmaceutical formulation of anti-her2 antibody and preparation thereof.'
Inventor(s) include Patel, Tushar; Mendiratta, Sanjeev Kumarn; Bandyopadhyay, Sanjay; Bhatt, Chandresh; and Patel, Chintan.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "The present invention provides novel stable pharmaceutical formulation of anti-HER2 antibody, preferably pertuzumab formulated in presence of arginine containing buffer(s), wherein the arginine containing buffer is selected from arginine-succinate buffer, arginine-phosphate buffer arginine-acetate buffer, arginine-aspartate buffer, arginine-citrate buffer and suitable combination thereof. The pharmaceutical formulation according to the present invention comprises pertuzumab and about 50 to about 500 mM of buffer(s) with one or more suitable excipients. Further, the present invention also provides the pharmaceutical formulation comprising therapeutically effective amount of anti-HER2 antibody, preferably pertuzumab antibody, buffer and amino acid(s) with one or more suitable excipient(s). In one of the aspects, the present invention provides liquid or lyophilized or frozen pharmaceutical formulation of anti-HER2 antibody preferably, pertuzumab. Other aspect of the present invention includes method of making pharmaceutical formulation of anti-HER2 antibody, preferably pertuzumab."
The patent application was internationally filed on Oct. 23, 2020, under International application No.PCT/IB2020/059985.
Disclaimer: Curated by HT Syndication.
